Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays
نویسندگان
چکیده
منابع مشابه
Clinical results with direct thrombin inhibitors.
Direct thrombin inhibitors inactivate thrombin without the need for antithrombin and some inactivate not only thrombin but also fibrin-bound thrombin. Hirudin has been shown to be more effective than low-dose unfractionated heparin and low molecular weight heparin for the prevention of deep vein thrombosis in high-risk orthopaedic patients. Major studies are assessing the value of direct thromb...
متن کاملDevelopment of Direct Thrombin Inhibitors
Anticoagulants are the cornerstone of therapy for conditions associated with arterial and venous thrombosis. Direct thrombin inhibitors (DTIs) are anticoagulants that bind to thrombin and block its enzymatic activity. The bivalent parenteral DTIs hirudin and bivalirudin were based on the observation that the salivary extracts of medicinal leeches prevented blood from clotting. Key events that f...
متن کاملEffects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Dabigatran is an oral, reversible thrombin inhibitor that has shown promising results in large clinical trials. Laboratory monitoring is not needed but the effects on common coagulation assays are incompletely known. Dabigatran was added to plasma from healthy subjects in the concentration range 0-1,000 μg/l and analysed using several reagents for activated thromboplastin time (APTT), prothromb...
متن کاملEffects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
INTRODUCTION Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays constitute clinically valuable information. OBJECTIVES To investigate the effects of apixaban on commonly used coagulation methods, and to evaluate anti-FXa assays ...
متن کاملOral direct inhibitors of coagulation.
For the first time in 50 years new oral anticoagulants of proven efficacy and with acceptable safety profiles are available for patients with atrial fibrillation and venous thromboembolism. Here is a brief overview of the benefits and possible disadvantages of using these drugs.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Clinical Pathology
سال: 2012
ISSN: 1943-7722,0002-9173
DOI: 10.1309/ajcpqod9wfpeyy0h